KVÄLLSSYMPOSIUM 2008 Vaccinering av hund och katt

More documents

Recommendations

Info

276 S.M. Moore et al. / Biologicals 33 (2005) 269e276 Acknowledgments The authors would like to thank the Centers for Disease Control and Prevention and Chiron Vaccines for donating the challenge viruses used in this study. In addition, our appreciation is extended to Dr Iris Stalkamp for providing phylogenetic data and sequence comparison information and to Dr Tony Stamp and Mal Hoover for their valuable assistance in preparing some of the figures used in this paper. References [1] Lafon M, Edelman L, Bouvet JP, Lafage M, Martchatre E. Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol 1990;71:1689e96. [2] Smith JS, Yager PA, Baer GM. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 1973;48:535e41. [3] Cliquet F, Aubert M, Sagné L. Development of a fluorescent antibody virus neutralization test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 1998;212:79e87. [4] Blancou J, Aubert MF, Cain E, Selve M, Thraenhart O, Bruckner L. Effect of strain differences on the potency testing of rabies vaccines in mice. J Biol Stand 1989;17(3):259e66. [5] Ferguson M, Wachmann B, Needy C, Fitzgerald EA. The effect of strain differences on the assay of rabies virus glycoprotein by single radial immunodiffusion. J Biol Stand 1987;15:73e7. [6] Smith JS. Molecular epidemiology. In: Jackson AC, Wunner WH, editors. Rabies. 1st ed. San Diego, CA, USA: Academic Press; 2002. p. 79e111. [7] Smith JS. Rabies serology. In: Baer GM, editor. The natural history of rabies. 2nd ed. Boca Raton, FL, USA: CRC Press; 1991. p. 235e52. [8] Tordo N. Characteristics and molecular biology of the rabies virus. In: Meslin FX, Kaplan MM, Koproski H, editors. Laboratory techniques in rabies. 4th ed. Geneva, Switzerland: World Health Organization; 1996. p. 28e51. [9] Maillard A, Gaudin Y. Rabies virus glycoprotein can fold in two alternative, antigenically distinct conformations depending on membrane-anchor type. J Gen Virol 2002;83:1465e76. [10] Smith JS, Yager PA, Baer GM. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. In: Meslin FX, Kaplan MM, Koproski H, editors. Laboratory techniques in rabies. 4th ed. Geneva, Switzerland: World Health Organization; 1996. p. 181e92. [11] Centers for Disease Control and Prevention. Human rabies prevention-United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;RR-1:1e21. [12] WHO Expert Committee on Rabies. 8th Report. Geneva, Switzerland: World Health Organization; 1992 [WHO Technical Report Series, No. 824]. [13] Code of Federal Regulations Title 21 Subpart A 320.1 Definitions. Food and Drug Administration, Health and Human Services. [14] Briggs DJ. Public health management of humans at risk. In: Jackson AC, Wunner WH, editors. Rabies. 1st ed. San Diego, CA, USA: Academic Press; 2002. p. 401e28. [15] Lodmell DL, Smith JS, Esposito JJ, Ewalt LC. Cross-protection of mice against a global spectrum of rabies virus variants. J Virol 1995;69:4957e62.
Nobivac ® Tricat Novum • Felint panleucopenivirus (stam MW-1) – 3 års duration • Felint herpesvirus (stam G2620A) – Årlig vaccination • Felint calicivirus (F9) – Årlig vaccination Continuum ® Feline HCP • Intervets kattvaccin i USA • 3 års DOI* indikation på alla komponenter • Samma som Nobivac ® Tricat *Gore et al. Vet Ther 2006 Nobivac ® kattvacciner Levande attenuerat vaccin För maximal effekt 11/20/2008Nov 2008 Anna-Karin Lieber Kvällssymposium: Vaccinering av hund och katt 11/20/200825–27 Nov 2008 2 Kvällssymposium: Vaccinering av hund och katt 11/20/200825–27 Nov 2008 3 1
Page 1: KVÄLLSSYMPOSIUM 2008 Vaccinering a
Page 4 and 5: Hundens parainfluensavirus typ 2
Page 7 and 8: Vet. Res. 38 (2007) 355-373 355 c
Page 9 and 10: animal colonies were found to carry
Page 11 and 12: An inactivated, subunit vaccine has
Page 13 and 14: was originally adopted after the in
Page 15 and 16: the S 1 gene of MRV belonging to di
Page 17 and 18: was reported, which was characteriz
Page 19 and 20: 1982, J. Am. Vet. Med. Assoc. (1982
Page 21 and 22: S.A., Munster V., Kuiken T., Rimmel
Page 23 and 24: [112] Miyoshi M., Ishii Y., Takiguc
Page 25: [155] Tong S., Li M., Vincent A., C
Page 28 and 29: Intranasala vacciner - fördelar
Page 30 and 31: Effektivitetsstudie skydd på 72 ti
Page 32 and 33: N o b i v a c ® K C Nobivac ® KC
Page 34 and 35: Jämförande studie mellan vaccinat
Page 37 and 38: Abstract The influence of homologou
Page 39 and 40: post-exposure vaccination regimen w
Page 41 and 42: Table 1 Titer of Challenge Virus St
Page 43: elated to the PM and Flury strains
Page 47: Nobivac ® kattvacciner flexibla va
Page 50 and 51: Vaccinering skall liksom annan medi
Page 52 and 53: Basvaccin - katt Basvaccin - hund K

KVÄLLSSYMPOSIUM 2008 Vaccinering av hund och katt

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?